跳至主要内容
临床试验/CTRI/2023/05/052687
CTRI/2023/05/052687招募中3 期

POLYMYXIN vs. CEFTAZIDIME-AVIBACTAM with AZTREONAM for primary treatment of Carbapenem Resistant Enterobacteriaceae (CRE) and Carbapenem Resistant Pseudomonas aeruginosa (CRPA) - CARE

AIIMS, Newdelhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 2.Sepsis (as per Sepsis-3 definition)
  • 3.CRE/PA detected on blood culture (Bact T Alert), followed by Malditof ID
  • 4.Carbapenemase gene positive PCR assay.

排除标准

  • 1.Refusal of consent
  • 2.Colistin resistance gene positive on PCR assay
  • 3.Patient not expected to survive more than 4 days (decided clinically)
  • 4.Patients on significant vasopressor support at the time of enrolment (defined as noradrenaline requirement more than 0.1 mcg/kg/min)
  • 5.Patient allergic to either of the drugs in the control or intervention group
  • 6.Patient with significant polymicrobial infection [coinfection with two different CRE, or CRE and CRPA, or CRE/CRPA and Acinetobacter Baumannii/gram positive bacteria (Gram positive skin contaminant in one set of blood cultures is not regarded as significant polymicrobial bacteraemia)].
  • 7.Pregnancy or breast feeding
  • 8.Significant pre-existing comorbidities – CKD 4/5, CLD
  • 9.Patients already receiving either CAZ-AVI/ATM or polymyxins prior to enrolment

研究者

发起方
AIIMS, Newdelhi

相似试验